| Top Large Companies (more than 5,000 employees) | Rank in 2006 | Rank in 2005 | Name/Location | Type | No. of R&D employees | Total No. of New Jobs in 2005 | 2005 Net Income | Significant developments
in the past year | | (among large companies) | | | | | | | | 1 | 3 | Amgen, USA | Biotechnology | 12,500
(all depts) | 1755
(US and Puerto Rico) | $3.1 billion
(2004) | Acquired Abgenix | | 2 | 1 | Genentech, USA | Biotechnology | 9,500
(all depts) | 1,500 | $6.6 billion | Acquired BioGen Idec's NIMO biologics manufacturing facility | | 3 | 9 | Monsanto, USA | Agricultural biotechnology | 1,900 | N/A | $6.3 billion
(global) | Acquired Seminis, Inc. and Emergent Genetics, Inc.; donated 700 metric tons of hybrid corn seeds to Malawi | | 4 | 12 | AstraZeneca, Sweden | Pharmaceutical | 5,000 | 95 | $6.5 billion
(global) | Acquired Kudos Pharmaceuticals, hired new CEO David Brennan | | 5 | 7 | Bristol-Myers Squibb, USA | Pharmaceutical | 5,000 | N/A | $3.0 billion | FDA approved three drugs: Baraclude, Orenicia, and Erbitux | | 6 | 13 | Novartis, USA | Pharmaceutical | 10,000 (global) | 600
(R&D global) | $6.1 billion
(global) | Acquired Chiron; received the Excellence in Corporate Philanthropy Award | | 7 | 13 | Novartis, Switzerland | | 8 | 13 | Novartis, UK | | 9 | - | Procter & Gamble, USA | Pharmaceutical, consumer goods | 9,000
(global) | N/A | $7.2 billion | Acquired the Gillette Company | | 10 | 11 | Johnson & Johnson, USA | Pharmaceutical, health care, consumer goods | 6,500 | 1,200 | $10.4 billion | Acquired six companies, including Transform Pharmaceuticals | | 11 | 2 | Pioneer Hi-Bred, USA | Agricultural biotechnology | 1,200 | N/A | $2.8 billion | Scientific lead for Gates Foundation-funded biofortified sorghum project in Kenya | | 12 | 9 | Monsanto, Canada | Agricultural biotechnology | 49 | 35 | $6.3 billion
(global) | Acquired Advanta Canada Seeds | | 13 | 13 | Novartis, Austria | Pharmaceutical | 10,000 (global) | 600 (R&D only, global) | $6.1 billion | See No. 6 above | | 14 | 14 | Wyeth, USA | Biopharmaceutical | 5500 | 200 (global) | $3.6 billion | Formed licensing deals with three biotech companies Progenics, Trubio, and Exelixis | | 15 | 12 | AstraZeneca, UK | Pharmaceutical | 12,000 (global) | N/A | $6.5 billion
(global) | See No. 4 above | | 16 | 15 | Sanofi-Aventis, USA | Pharmaceutical | over 2,400 | N/A | €6.3 billion
(global) | Reached agreement with Roche for production of key ingredient in Tamiflu | | 17 | 5 | Pfizer, USA | Pharmaceutical | 12,500 | N/A | $8.1 billion | Acquired Vicuron Pharmaceuticals and Bioren, Inc. | | 18 | 22 | Bayer Healthcare, USA | Health care, nutrition | private | private | €8.3 billion
(entire Bayer Corporation) | Purchased prior business from GlaxoSmithKline | | 19 | 6 | Merck and Co., USA | Pharmaceutical | almost 8,000 | 982
(R&D only) | $4.6 billion | Submitted three new drug applications to FDA | | 20 | 8 | Abbott Laboratories, USA | Pharma, nutritional, devices/diagnostics | 7000 in US | 5000 | $3.2 billion (2004) | Acquired Guidant's vascular business |
|
